A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Active, not recruiting · Phase 2 · NCT06660654
Conditions: Advanced Solid Tumor, Metastatic Solid Tumors
At a glance
- Research payments reported, 2025
- $987,972
- U.S. investigators named
- 13
- Sites paid
- 17
- Planned or actual enrollment
- 335
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- Raludotatug deruxtecan (drug)
- Dates
- Started 2025-01-06; completion 2029-12-30
- Results posted
- Not yet
This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).
From ClinicalTrials.gov, last updated 2026-09-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $987,972 in research payments for this study in 2025 (757 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nataliya Mar, MD Hematology & Oncology · Orange, CA
- Matthew P. Schlumbrecht, MD Gynecologic Oncology · Miami, FL
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- Louis C. Garrot, M.D. Hematology & Oncology · Marietta, GA
- Jean H. Siedel, D.O. Gynecologic Oncology · Ann Arbor, MI
- Siu-long Yao, M.D. Hematology & Oncology · East Brunswick, NJ
- Joyce N. Barlin, M.D. Gynecologic Oncology · Albany, NY
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Gopakumar V. Iyer, M.D. Internal Medicine · New York, NY
- Kathleen N. Moore, MD OB-GYN (Obstetrics & Gynecology) · Oklahoma City, OK
- Michael Ulm, M.D, M.S. Gynecologic Oncology · Germantown, TN
- Sarina A. Piha-paul, M.D. Medical Oncology · Houston, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $361,998
- West Cancer Center and Research Institute-East Campus $176,503
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $90,194
- The University of Oklahoma Health Sciences Center $84,711
- University of Michigan Health System, MI $57,523
- Clinical Research Alliance $57,074
- Uci Health-Orange, CA $47,210
- Adventhealth Orlando, FL $34,613
- Womens Cancer Care Associates LLC $24,889
- Titan Health PArtners, Llc $20,642
- Virginia Cancer Specialists Fairfax $15,684
- University of Miami $10,660
- Ou Health Stephenson Cancer Center $2,252
- Northside Hospital Gwinnett, GA $1,480
- University of Miami Hospital $1,480
- Astera Cancer Care East Brunswick $594
- Samuel Oschin Cancer Center $467
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.